Hikma Pharmaceuticals PLC (LSE:HIK) - Share price

Stock Report

Hikma Pharmaceuticals PLC HIK

Last Price

Day Change

As of 04/08/2021
17:43:01 BST | GBX
Minimum 15 Minutes Delay.

Last Close2,690.00p
Day Range2,638.00 - 2,695.00
Mkt Cap6.23Bil
52-Wk Range2,141.00 - 2,768.00
Yield %1.37

Share Price

Total Returns 03/08/2021

 Chg (%)  
More ...
Hikma Pharmaceuticals PLC5.78 
FTSE 100 TR GBP-0.12
More ...
Income Statement
Operating Profit371.00449.00560.00
Net Profit285.00487.00430.00
Reported EPS1.172.001.81
Balance Sheet
Current Assets1,668.001,848.001,922.00
Non Current Assets1,829.002,082.002,213.00
Total Assets3,497.003,930.004,135.00
Current Liabilities893.001,471.001,028.00
Total Liabilities---
Total Equity1,697.002,129.002,148.00
Cash Flow
Operating Cash Flow493.00580.00525.00
Net Change in Cash56.00166.00-117.00

Regulatory News

DateAuthor Headline
26/09/2019James Gard Job Curtis Backs St James's Place
FTSE 100 wealth manager, which has come under fire for adviser perks recently, is the 20th largest holding in the Silver-rated City of London Investment Trust
28/05/2019James Gard Galliford Try Rejects Bovis Approach
Talks with FTSE 250 housebuilder Bovis to buy Galliford's housebuilding arm have broken down
18/02/2019David Brenchley Stellar Year for Global Dividends in 2018
Global dividends grew faster last year than at any point since 2015, data from asset manager Janus Henderson show. But growth in 2019 is set to slow
Director Dealings
More ...
17/05/2021Transfer inMr. Mazen Samih Taleb Darwazah0.0012,0420.00
17/03/2021PurchaseMs. Nina Henderson2,203.001,60035,248.00
12/03/2021Transfer inMr. Mazen Samih Taleb Darwazah0.0042,5720.00
12/03/2021Transfer inMr. Said Darwazah0.0061,6660.00

Company Profile

Founded in the Middle East with headquarters in London, Hikma manufactures generic and in-licensed pharmaceuticals. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.


Drug Manufacturers - Specialty & Generic


FTSE 100 , FTSE 350 , FTSE All Share

Next Event 06/08/2021

Half-Yearly Results
More ...
PER (E)20.40
Div Yld (E)1.39
PEG (E)0.00
Op Mrgn0.24
EPS Grwth-0.09
More ...
Record Date21/08/2019/03/21
More ...
Non-Executive DirectorDr. Pamela Josephine Kirby
Executive Director, Vice ChairmanMr. Mazen Samih Taleb Darwazah
Non-Executive DirectorMr. Mohammed Ali Khaldoun S Al-Husry
Non-Executive DirectorMr. Douglas Michael Hurt
Executive Director, ChairmanMr. Said Darwazah
Executive Director, Chief Executive OfficerMr. Sigurdur Olafsson
Non-Executive DirectorMs. Nina Henderson
Non-Executive Director, Senior Independent DirectorMr. Patrick Butler
Non-Executive DirectorMr. John Julius Castellani
Non-Executive DirectorMs. Cynthia L. Schwalm
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.